Receptor-mediated internalization to the endoplasmic reticulum (ER) and subsequent retro-translocation to the cytosol are essential sequential processes required for the productive intoxication of susceptible mammalian cells by Shiga-like toxin-1 (SLTx). Recently, it has been proposed that the observed association of certain ER-directed toxins and viruses with detergent-resistant membranes (DRM) may provide a general mechanism for their retrograde transport to endoplasmic reticulum (ER). Here, we show that DRM recruitment of SLTx bound to its globotriosylceramide (Gb 3 ) receptor is mediated by the availability of other glycosphingolipids. Reduction in glucosylceramide (GlcCer) levels led to complete protection against SLTx and a reduced cell surface association of bound toxin with DRM. This reduction still allowed efficient binding and transport of the toxin to the ER. However, toxin sequestration within DRM of the ER was abolished under reduced GlcCer conditions, suggesting that an association of toxin with lipid microdomains or rafts in the ER (where these are defined by detergent insolubility) is essential for a later step leading to or involving retro-translocation of SLTx across the ER membrane. In support of this, we show that a number of ER residents, proteins intimately involved in the process of ER dislocation of misfolded proteins, are present in DRM.
INTRODUCTION
Shiga-like toxin 1 (SLTx) is a potent ribosome-inactivating protein produced by certain enterohemorrhagic strains of Escherichia coli and is virtually identical to Shigella toxin (STx). It consists of a single A-chain possessing rRNA-specific N-glycosidase activity (Endo et al., 1988) and five noncovalently associated B-subunits (SLTxB) that are responsible for binding and uptake into target cells (Pudymaitis et al., 1991; Sandvig et al., 1994; Ling et al., 1998) . To inactivate ribosomes, SLTx (or at least the enzymatic A subunit) must traverse an internal membrane, thought to be the endoplasmic reticulum (ER) membrane. This is also the retro-translocation site for internalized STx, cholera toxin (CTx), ricin, E. coli heat-labile enterotoxin, pertussis toxin, and Pseudomonas exotoxin A Lord et al., 2003; Roberts and Smith, 2004; Sandvig et al., 2004) whose substrates also reside within the cytosol. Although the details of toxin translocation remain sketchy, it is thought that these proteins can co-opt ER components and exploit the ER retrotranslocation machinery normally used in the perception and dislocation of newly made but misfolded or orphan polypeptides in readiness for their destruction by proteasomes. To be effective, however, the toxins must somehow uncouple from downstream cytosolic steps to avoid being completely degraded (Hazes and Read, 1997; Deeks et al., 2002; Rodighiero et al., 2002) .
To reach the ER, SLTx must first bind, through the B subunits, to its globotriaosylceramide (Gb 3 /CD77) receptors at the plasma membrane (Jacewicz et al., 1986) . Internalization of the toxin is known to proceed via the endosomal system and the trans-Golgi network in a process that bypasses late endosomes (Mallard et al., 1998; Mallard et al., 2002) . This is followed by coatomer protein 1-independent transport through the Golgi to the ER (Girod et al., 1999; White et al., 1999) . Although the extent and identity of cellular proteins trafficking from the plasma membrane to the early Golgi and ER are not fully known, the retrograde trafficking of some glycosphingolipids (GSL) to the Golgi has been recognized (Puri et al., 2001) . It has recently been proposed that the retrograde routing of GSL-binding toxins to the ER involves association of the toxin/GSL complex with lipid microdomains (Fujinaga et al., 2003) , often referred to as lipid rafts that are enriched in certain GSL, specific proteins, and cholesterol (Simons and Ikonen, 1997; Brown and London, 2000) . These are isolated on the basis of detergent resistance, and the resulting detergent-resistant membranes (DRM) are interpreted to represent lipid microdomains in the original membrane. Indeed, there is a strong correlation between the ER routing of the B-chain of the related STx and its association with DRM in toxinsensitive HeLa cells. By contrast, in a macrophage cell line in which DRM association of STx B was not observed, the toxin was directed to lysosomes, and the cells survived (Falguieres et al., 2001) .
Recently, it has been shown that the normal retrograde transport of an internalized GSL, lactosylceramide (LacCer), to the Golgi can be altered dramatically by chemical modulation of endogenous glucosylceramide (GlcCer) levels (Sillence et al., 2002) . Indeed, treatment of RAW macrophages with the imino sugar N-butyldeoxygalactonojirimycin (NB-DGJ), a specific inhibitor of ceramide glucosyltransferase (Andersson et al., 2000) , resulted in lysosomal targeting of LacCer (Sillence et al., 2002) . A question arising from this is whether modulation of cellular GlcCer levels also affects the trafficking and cytotoxicity of SLTx.
In the present study, we have investigated the effect of NB-DGJ on the intracellular uptake and cytotoxicity of SLTx. We show that NB-DGJ completely protected both Vero and HeLa cells from SLTx intoxication. Furthermore, we have shown that the affinity of toxin for DRM was modulated by the presence of GlcCer, such that its partitioning into DRM was lowered at the plasma membrane and abolished within the ER upon treatment with the inhibitor. Membrane binding and subsequent retrograde transport of toxin to the ER was unaffected by NB-DGJ treatment. This result led us to propose that SLTx requires an association with lipid rafts within the ER membrane for efficient retro-translocation to the cytosol. In support of this, we have demonstrated that certain ER-resident proteins, which are intimately involved in the retro-translocation process, are themselves sequestered into DRM.
MATERIALS AND METHODS

Sources
NB-DGJ was purchased from Calbiochem (San Diego, CA). Antibodies were kindly provided against calnexin, ribophorins, and Sec61␤ by Steve High (University of Manchester, Manchester, United Kingdom), Derlin-1 and VIMP by Tom Rapoport (Harvard University, Cambridge, MA), and SLTx by Arthur Donohue-Rolfe (Tufts University, Boston, MA). Antibody against protein disulfide isomerase (PDI) was purchased from Stressgen Biotechnologies (Victoria, British Columbia, Canada), and antibody against transferrin receptor was purchased from Zymed (South San Francisco, CA). Radioisotopes were from GE Healthcare (Little Chalfont, Buckinghamshire, United Kingdom). Cross-linkers and IODO-BEADS iodination reagent were obtained from Pierce Chemical (Cheshire, United Kingdom). Cyclosporin A came from Sigma (Poole, Dorset, United Kingdom). Glucosylsphingosine came from Matreya (Universal Biologicals, Stroud, United Kingdom).
Cell Lines
All cell lines were maintained in RPMI 1640 medium containing 2 mM l-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (Invitrogen, Carlsbad, CA), and 5% fetal calf serum (Labtech, Ringmer, United Kingdom).
Cytotoxicity Assays
Cells were seeded at 2.5 ϫ 10 4 cells/well into flat-bottomed 96-well plates and grown overnight. Cells were then overlaid with medium containing appropriate concentrations of SLTx for 4 h. Remaining cellular protein synthesis after toxin treatment was determined as the incorporation of [
35 S]methionine into total protein as described previously (Deeks et al., 2002; Smith et al., 2003) 
Biochemistry, Binding, and Internalization Analysis
Protein iodination, Scatchard analysis, and glycosylation analysis were performed as described previously (Johannes et al., 1997; Mallard et al., 1998; Spooner et al., 2004) .
Preparation and Analysis of DRM from HeLa and L3/bcl-2 Cells
DRM were prepared as published previously (Benting et al., 1999; Falguieres et al., 2001) . Briefly, the required amount of cells for 300 g of total protein was washed once with phosphate-buffered saline (PBS) and resuspended in 0.2 ml of 2ϫ TNE (1ϫ TNE: 25 mM Tris-HCl ,pH 7.4, 150 mM NaCl, 2.5 mM EDTA, and a mixture of protease inhibitors containing phenylmethylsulfonyl fluoride, leupeptin, chymostatin, pepstatin, antipain, and aprotinin). All steps were performed on ice. Cells were lysed by passage through a ball homogenizer (20 times). The postnuclear supernatant (PNS) was collected after a spin at 4°C, 3000 ϫ g for 10 min; the 0.2-ml volume was added to an equal volume of 2% Triton X-100 (Tx-100), and the mixture was incubated on ice for 30 min. OptiPrep (Sigma) was added to a final concentration of 40%. The solutions were overlaid with 2.3 and 0.8 ml of 30 and 5% OptiPrep in TNE, respectively, and spun at 4°C, 28,000 rpm, for 4 h (SW41 rotor; Beckman Coulter, Fullerton, CA). The gradient was fractionated manually from the top. DRM were found at the 5/30% interface. To analyze the fractions, Western blotting and dot blot analysis were performed according to standard procedures.
Glycolipid Extraction from L3/bcl-2 Cells and Toxin Overlay
Lipid extraction was carried out according to the published method (Bligh and Dyer, 1959) , with the previously described modifications (Falguieres et al., 2001 ), as described above. After DRM gradient fractionation, the isolated neutral glycolipids were spotted on high-performance thin layer chromatography (TLC) plates (Merck, Darmstadt, Germany) and separated with chloroform/methanol/water (65:25:4). Dried plates were soaked in 0.1% polyisobutylmethacrylate in hexane and floated for 1 h in blocking solution, followed by incubation with 20 nM SLTxB, primary polyclonal anti-SLTxB, and secondary horseradish peroxidase, or alkaline phosphatase-coupled antirabbit antibodies. Reactive bands were revealed with the use of enhanced chemifluorescence (GE Healthcare) and PhosphorImager.
Isolation of DRM for Lipid Analysis
DRM were purified as published previously (Lisanti et al., 1995) . Briefly, tissues were homogenized with 10 strokes of a Dounce homogenizer in PBS. The PNS was collected after a spin at 4°C, 3000 ϫ g for 10 min, the volume was added to an equal volume of 1% Tx-100, and the mixture was incubated on ice for 30 min. The solution made up to 40% sucrose and transferred to a Beckman Ultraclear 14 ϫ 89-mm tube on ice, and a discontinuous gradient of 5 ml of 30% sucrose and 3 ml of 5% sucrose was layered on top. Samples were ultracentrifuged in a SW41 rotor at 100,000 ϫ g for 16 h at 4°C, and 2-ml fractions were manually collected.
Purification and Preparation of GSL for HPLC
GlcCer was purified on silicic acid columns, washed with 2 ml of CHCl 3 and 2 ml of CHCl 3 /MeOH (98:2). GlcCer was eluted with 2 ml of CHCl 3 /MeOH (97:3), 2 ml of CHCl 3 /MeOH (96:4), 2 ml of CHCl 3 /MeOH (95:5), and 2 ml of CHCl 3 /MeOH (94:6), and dried down and resuspended in 15 l of 50 mM sodium acetate buffer, pH 5, with 0.1% Triton and 0.25% taurocholate. Then, 0.4 U of purified glucocerebrosidase (cerezyme) was added and incubated at 37°C for 18 h. Samples were derivatized using the same method as for the GSL. Other GSL were extracted by the addition of 3.2 vol of CHCl 3 /MeOH (1:2.2) for 10 min at room temperature, and the phases were split by the addition of 1 vol of CHCl 3 and 1 vol of H 2 O (Bligh and Dyer, 1959) . This quick extraction procedure gave similar recoveries of GSL to other commonly used methods of lipid extraction (van Echten et al., 1990; Miller-Podraza et al., 1992 ). Upper phase GSL were then recovered by SePak C18 columns (Sillence et al., 2000) . Briefly, C18 SepPak columns (Waters, Milford, MA) were washed with 1 ml of MeOH and 1 ml of water. The CHCl 3 phase was dried down and loaded in 50 l of CHCl 3 /MeOH (1:3). The corresponding aqueous phase was loaded onto the columns and washed with 1 ml of water five times. GSL were then eluted with 1 ml of CHCl 3 /MeOH (1:3) five times and 1 ml of MeOH, and the samples were dried under nitrogen. At this point, the cholesterol and GSLs were quantified as described below. For mass spectrometry, the samples were saponified by the addition of 1 ml of CHCl 3 and 1 ml of 0.2 M NaOH in methanol and incubated overnight at 37°C and further purified by silicic acid chromatography (Vance and Sweeley, 1967) . Silicic acid columns were pre-equilibrated in CHCl 3 , and the samples were loaded onto the column and washed with 5 ml of CHCl 3 . Neutral GSL were eluted with 6 ml of acetone/ MeOH (9:1). Gangliosides were eluted with 6 ml of CHCl 3 /MeOH (1:3), and the eluates were dried under nitrogen. The samples were resuspended with 1 ϫ 50 l and then 1 ϫ 100 l of CHCl 3 /MeOH (1:2.2) and transferred to a 1.5-ml tube. The samples were dried down in a SpeedVac and resuspended in 20 l of MeOH.
Quantitation of GSL Derivatives by High-Performance Liquid Chromatography (HPLC)
GSL were analyzed according to Neville et al. (2004) . To dried lipid extracts, 10 l of incubation buffer (1 mg/ml sodium cholate in 50 mM sodium acetate, pH 5.0) was added. After vigorous vortexing and spinning in a benchtop picofuge, 10 l of 50 mU/10 l ceramide glycanase (E.C. 3.2.1.123; Calbiochem) in incubation buffer was added to cleave the glycans. Glucosylceramide is partially digested because of the specificity of the glycanase (Wing et al., 2001) . After this period, 10 l of water was added to each enzyme digest followed by 80 l of anthranilic acid and sodium cyanoborohydride to each digest and incubated in the 80°C oven for 1 h. Derivatized oligosaccharides were then purified on DPA-6S (Supelco, Bellefonte, PA) columns preequilibrated with 2 ϫ 1 ml CH 3 CN. One milliliter of 97:3 CH 3 CN/H 2 O was added to each sample and vortexed before loading the samples onto the columns. Columns were washed with 1 ml of 99:1 CH 3 CN/H 2 O four times and then with 0.5 ml of 97:3 CH 3 CN/H 2 O, and the derivatized oligosaccharides were eluted with 0.6 ml water two times into screw-cap Eppendorfs and stored at 4°C in the dark until ready for normal phase-HPLC.
Mass Spectrometry
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry was performed as described previously . Briefly, a mixture of the sample (1 l; 100 pmol) and matrix (1 l of a saturated solution of 2,5-dihydroxybenzoic acid in acetonitrile) was crystallized on the MALDI target. Positive ion reflectron MALDI spectra were obtained with a Micromass TOFSpec 2E mass spectrometer equipped with delayed extraction (Micromass UK, Wythenshawe, Manchester, United Kingdom). The instrument was operated as follows: accelerating voltage, 20 kV; pulse voltage, 3200 V; and laser repetition rate of 10 Hz and calibrated externally with hydrolyzed dextran sugars.
Immunofluorescence Methods
HeLa cells were fixed at room temperature for 20 min in 3% paraformaldehyde, quenched with 30 mM glycine, permeabilized with 0.1% Tx-100, incubated with the indicated primary or secondary antibodies, mounted, and viewed by confocal microscopy (Leica Microsystems, Mannheim, Germany). For Tx-100 extraction on living cells, the cells were put on ice, washed once with PBS containing 1 mM MgCl 2 and 0.5 mM CaCl 2 , and incubated for 1 min in 1% Triton/PIPES buffer (80 mM PIPES, pH 6.8, 5 mM EGTA, and 1 mM MgCl 2 ). The buffer was then removed and 3% paraformaldehyde was added for 15 min at room temperature as described previously (Falguieres et al., 2001) .
RESULTS
The Toxicity of SLTx Is Completely Abrogated upon Treatment with NB-DGJ, an Inhibitor of Glycosphingolipid Biosynthesis
For a productive intoxication of susceptible mammalian cells, SLTx is required to bind its GSL receptor, Gb 3 , for uptake and delivery to the ER lumen from where the toxin is dislocated to the cytosol to inactivate ribosomes (Sandvig and van Deurs, 2002; . Because treatment of fibroblasts and macrophages with NB-DGJ redirects endocytosed GSL (LacCer), away from the Golgi and into lysosomes (Sillence et al., 2002) , we investigated whether NB-DGJ could similarly alter the cell entry and therefore the potency of SLTx. The cytotoxic effect of SLTx on cellular protein biosynthesis was measured by incubating cells with increasing concentrations of the toxin (Figure 1 ). When HeLa and Vero cells were pretreated with NB-DGJ for 16 h before a 4-h toxin challenge in the continued presence of the drug, cellular protein synthesis was unaffected ( Figure 1 , A and C). Similar protection was seen with DL-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, a chemically unrelated inhibitor of glucosylceramide synthesis (our unpublished data). A significant protection was also seen after a short 2-h pretreatment with the drug (Figure 1 , B and D). Because HeLa cell sensitivity to SLTx could be modulated by NB-DGJ in a time-and concentration-dependent manner (our unpublished data), with maximal protection seen after 2 h with 100 M NB-DGJ ( Figure 1B ), all subsequent experiments were performed under these conditions. Because NB-DGJ is an inhibitor of GSL biosynthesis, both GSL composition and binding studies were performed with SLTx after a 2-h pretreatment with 100 M NB-DGJ. Analysis of the GSL composition in HeLa cells treated with 100 M NB-DGJ (2 h) showed that the total levels of Gb 3 remained unaltered, whereas the levels of GlcCer decreased to ϳ38% of control cell levels, with reductions also seen in the levels of II 3 -␣-N-acetylneuraminyllactosylceramide (GM3) and neolactotetraglycosylceramide (nLc 4 ) ( Table 1) . Consistent with this, Scatchard analysis demonstrated that the binding affinity and number of SLTx receptor sites (i.e., Gb 3 ) remained essentially unaltered compared with controls (Table 2). Interestingly, the levels of LacCer, the next GSL to be synthesized sequentially from GlcCer, remained unaltered after NB-DGJ treatment (Table 1) . Analysis of the Tx-100-resistant fraction isolated from NB-DGJ-treated cells highlighted changes within the level of all the GSL examined, with the exception of LacCer, with significant changes occurring for GlcCer and Gb 3 , implying that inhibition of GSL biosynthesis rapidly altered the composition of these lipids in DRM. Cells remained sensitive to SLTx when NB-DGJ was coadministered with the toxin; furthermore, NB-DGJ pretreatment had no effect on the cytotoxicities of two other ER-directed protein toxins, Pseudomonas exotoxin A and ricin (our unpublished data). Together, these findings rule out as explanations for the SLTx-resistance phenotype a lack of surface receptors, a perturbation of the toxin uptake pathways, and, because of the identical catalytic mechanism of SLTx and ricin (Furutani et al., 1992) , a direct inhibitory effect of the drug upon the SLTx active site.
Trafficking of SLTx to the ER Is Not Perturbed by NB-DGJ Treatment
Productive intoxication with SLTx requires the initial binding of toxin to surface Gb 3 molecules followed by retrograde transport of the complex to the ER. The length of the Gb 3 fatty acyl chain is important for efficient ER targeting of the toxin, with the presence of the shorter chain (C16 -C18) isoforms being associated with enhanced cellular sensitivity and ER targeting of SLTx (Sandvig et al., 1994; Arab and Lingwood, 1998) . We therefore examined the possibility that NB-DGJ treatment was altering the availability of shorter chain Gb 3 isoforms, thereby disrupting transport to the ER. However, mass spectrometric analysis of the chain lengths of Gb 3 isoforms isolated after NB-DGJ treatment showed no significant difference compared with control cells (Table 3) . Because treatment with NB-DGJ is known to alter trafficking of LacCer to the lysosomes in certain cell types (Sillence et al., 2002) , we next examined whether the intracellular routing of SLTx had been altered after NB-DGJ treatment. The routing of toxin to the ER can be monitored and quantified using a radiolabeled SLTx-B chain variant engineered to contain a glycosylation sequence that becomes posttranslationally core glycosylated upon arrival in the ER (Johannes et al., 1997) . Using such an approach, the amounts of core glycosylated, radiolabeled SLTxB were identical in NB-DGJtreated HeLa cells and in control cells (Figure 2 ). The coreglycosylated SLTxB moieties disappeared upon tunicamycin treatment of the cells (Figure 2A) , confirming that the proteins detected had become glycosylated, a modification that is only possible within the ER lumen. This clearly demonstrated that SLTx transport to the ER is unaltered by NB-DGJ treatment. It should be noted that this atypical, posttranslational N-glycosylation of a protein entering the ER from the Golgi is generally inefficient. The proportion of SLTx glyco- sylated in this way is on a par with previously reported levels (Falguieres et al., 2001) .
SLTx Can Be Associated with DRM in the ER Membrane
Because SLTx was still efficiently transported to the ER after NB-DGJ treatment, we hypothesized that the mechanism through which protection against the toxin was observed may reside at the level of the ER. ER targeting of SLTx has been correlated to an association with DRM at the plasma membrane (Falguieres et al., 2001; Hoey et al., 2003) . This association persisted through to the ER, as shown by the presence of ER-glycosylated SLTxB-KDEL in DRM (Falguieres et al., 2001) . It was therefore pertinent to test whether SLTx persisted within DRM in the ER membrane after NB-DGJ treatment. To examine this, iodinated "glycosylatable" SLTxB was bound and internalized into HeLa cells for 4 h after pretreatment with NB-DGJ. DRM association of ERlocalized (i.e., glycosylated) SLTxB was investigated using the technique of buoyant density-gradient centrifugation after extraction in the presence of cold Tx-100, a widely accepted method for the isolation of DRM Simons and Toomre, 2000) . Gradient fractions were isolated and analyzed for the presence of the ERlocalized glycosylated SLTxB. Our data confirmed the previous observation (Falguieres et al., 2001 ) that in control cells, a proportion of the ER-glycosylated SLTxB was localized to DRM ( Figure 3A , asterisk, top). This result was supported visually. After 4 h of toxin treatment, a significant amount of fluorescently labeled SLTx could be seen within the reticular and perinuclear ER structures, along with a proportion of the ER marker, Sec61␤ ( Figure 3B , top row). After treatment with cold 1% Tx-100, a fraction of the SLTx and Sec61␤ was extracted, but a significant proportion remained, and the two proteins displayed a degree of overlap around the perinuclear and peripheral ER area ( Figure 3B , second row). This suggested that they had a specific distribution within the ER, possibly reflecting their presence in lipid microdomains in the ER membrane before detergent treatment. On treating cells with NB-DGJ followed by internalization of iodinated SLTxB, no glycosylated SLTxB was detectable within the DRM fraction ( Figure 3A , second panel, lane 2). Nevertheless, the same proportion of SLTxB became glycosylated as in the untreated cells ( Figure 3A , top). Transport to the ER after NB-DGJ treatment was also supported by the localization of SLTx within perinuclear reticular structures ( Figure 3B , third row). However, after cold Tx-100 extraction, SLTx was completely solubilized from NB-DGJ-treated cells, whereas an appreciable proportion of the Sec61␤ remained ( Figure 3B , fourth row). Together, these data revealed that a proportion of SLTx is normally found with DRM within the ER and that this association was abolished upon treatment with NB-DGJ.
NB-DGJ Alters the Recruitment or Association of SLTx into DRM
Because NB-DGJ treatment abolished DRM association of SLTx within the ER membrane, we next investigated DRM DRM were floated in OptiPrep step gradients. The gradients were fractionated, and the presence of the SLTx-B was determined by gel electrophoresis. G 0 and G 1 (*) indicate the unmodified and the ER-located glycosylation product, respectively. Quantitation of G 1 (% of total) was determined from three independent experiments. Gradients were also analyzed by dot-blot for GM 1 (DRM marker) and by gel electrophoresis and blotting for a non-DRM marker, the transferrin receptor (TnF-R). (B) Cy2-coupled SLTx-B was bound to the plasma membrane of control or NB-DGJ (100 M; 2 h)-treated HeLa cells on ice and washed and shifted to 37°C for 4 h. Cells were then washed and placed on ice, incubated (Tx-100) or not for 1 min in cold 1% Tx-100-containing buffer, and then fixed and permeabilized. Cells were then probed with a primary Sec61␤ antibody, washed, and incubated with an Alexa 633-coupled secondary antibody, mounted, and viewed by confocal microscopy. Bar, 5 m.
association of SLTx bound at the cell surface at 4°C. In agreement with a previous study (Falguieres et al., 2001) , ϳ40% of the bound SLTx was sequestered within the isolated GM 1 -containing DRM fraction of untreated cells as determined using resistance to extraction in cold 1% Tx-100 and subsequent flotation based on buoyant density ( Figure  4A) . Interestingly, the level of SLTx found with the DRM fraction was reduced from 40 to 22% after treatment of cells with the drug (Figure 4B ). This correlated well with the halving of DRM-sequestered Gb 3 after NB-DGJ treatment (Table 1) . However, although there was less toxin associated with isolated DRM, enough SLTx remained within such lipid microdomains in the plasma membrane in vivo to permit transport to the ER. Interestingly, the DRM association of SLTxB observed in macrophages, where toxin is routed to the lysosome, was Ͻ2% of the total toxin bound (Falguieres et al., 2001) . If the recruitment of Gb 3 into lipid rafts occurs upon toxin binding in HeLa cells, as has been suggested (Falguières and Johannes, unpublished data), then a prediction arising from this is that NB-DGJ treatment should have little or no effect on Gb 3 molecules already associated with lipid rafts before toxin binding and therefore have correspondingly little or no effect on SLTx cytotoxicity. Indeed, the cytotoxicity observed with SLTx was not significantly altered after either a 2-h ( Figure 5A ) or 16-h (our unpublished data) NB-DGJ pretreatment of a Burkitt's lymphoma derived-line, L3/ bcl-2, in which a high level of Gb 3 is found associated at all times within the isolated DRM fraction ( Figure 5B ). This implied that the binding of ligand to Gb 3 did not alter its DRM association in this cell type. The amount of Gb 3 found with DRM was not affected after drug treatment (our unpublished data). Indeed, analysis of L3/bcl-2 cells shows that after a 2-h treatment with NB-DGJ, there was no significant effect on the levels of the GSL examined (Table 4) . However, after 16 h the level of GlcCer was decreased by ϳ50% showing that L3/bcl-2 cells were nevertheless sensitive to the drug. Furthermore, there was no change in the level of SLTx found in the DRM fraction after NB-DGJ treatment compared with control cells (Figure 5, C and D) . This was in marked contrast to the situation seen in HeLa cells (Figure 4 ). These findings support our prediction that NB-DGJ perturbs the recruitment to and/or the affinity of SLTx/Gb 3 complexes to associate with lipid rafts at the cell surface.
DRM Association of SLTx/Gb 3 Can Be Influenced by the Levels of Glucosylceramide
Because NB-DGJ specifically inhibits ceramide glucosyltransferase (Platt et al., 1994) , an enzyme that catalyzes the first step in GSL biosynthesis located in the cis-Golgi, it was not immediately obvious how this drug was able to perturb recruitment of SLTx into lipid rafts at the plasma membrane. However, this phenomenon might be explained by the levels of available GlcCer in the cell. NB-DGJ inhibits synthesis of GlcCer from ceramide, thus reducing production of GSL (Platt et al., 1994; Andersson et al., 2000) . Indeed, after treatment with NB-DGJ the DRM-associated GlcCer was reduced by ϳ50% in a 2-h period in HeLa cells (Table 1) , whereas the level of LacCer in DRM-the GSL directly synthesized from GlcCer-was not significantly changed (Table 1) . We reasoned that the level of GlcCer may therefore influence the affinity of surface-bound SLTx for DRM. To address this, we introduced exogenous Gb 3 into GM95 cells that have very low levels of endogenous GSL and that completely lack Gb 3 (Ichikawa et al., 1994) . After overnight incubation, ϳ20% of the Gb 3 became sequestered into the DRM fraction after toxin binding ( Figure 6A ). When GM95 cells were coincubated with Gb 3 and glucosylsphingosine (GlcSph), a compound that can be acylated to increase the concentration of cellular GlcCer (Farrer and Dawson, 1990) , the amount of toxin-bound Gb 3 in DRM increased to Ͼ50% ( Figure 6A) . The increased population of the complex within DRM did not arise from a conversion of GlcCer to Gb 3 , because GM95 cells lack Gb 3 synthase (Ichikawa et al., 1994) . In accordance with this, an increase in the total level of Gb 3 was not observed ( Figure 6B ). By contrast, cellular II 3 -␣-N-acetylneuraminyllactosylceramide (GM3) levels did increase after GlcSph treatment ( Figure 6B) , showing that the additional GlcCer generated from the added GlcSph had allowed an increase in the levels of other GSL. These data suggest that the levels of GlcCer can influence, directly or indirectly, the amount of bound toxin that becomes recruited to DRM.
We then modulated the activity of P-glycoprotein (MDR-1) because it is known that overexpression of MDR-1 leads to an increased translocation of GlcCer into the Golgi lumen (Lala et al., 2000; Eckford and Sharom, 2005) , raising the supply of this lipid for the synthesis of other GSL, including Gb 3 . We reasoned that the effect of inhibiting Tx-100. DRM were floated in OptiPrep step gradients. The gradients were fractionated and the presence of bound SLTx was determined by gel electrophoresis and Western blotting and quantified using enhanced chemifluorescence. Gradients were also analyzed by dotblot for GM 1 (DRM marker) and by gel electrophoresis and blotting for a non-DRM marker, the transferrin receptor (TnF-R). Means of three experiments (ϮSEM) are shown.
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MDR-1 activity should therefore be similar to that seen for NB-DGJ treatment. Indeed, when we examined the amount of SLTx associated with DRM after a 2-h pretreatment of HeLa cells with the well characterized MDR-1 inhibitor cyclosporine A (CsA) (Lavie et al., 1997; Landwojtowicz et al., 2002; Eckford and Sharom, 2005) , it was found to be reduced ( Figure 6C ) compared with control cells ( Figure 4A ). Furthermore, when HeLa cells were pretreated with CsA (10 M; 2 h), they displayed appreciable resistance to a toxic challenge with SLTx ( Figure 6D ). GSL analysis revealed that treatment of HeLa cells with CsA (10 M; 2 h) reduced both the total levels and DRM association of GlcCer (Table 5) . DRM-associated Gb 3 was also reduced after CsA treatment, but the total cellular pool remained unaffected (Table 5) . Interestingly, no protection from SLTx cytotoxicity was observed in L3/bcl-2 cells treated with CsA (10 M; 2 h) (our unpublished data), a finding that correlated well with the unperturbed levels of GlcCer and Gb 3 in these cells (Table 4) . Together, the data suggest that the degree of DRM association of SLTx/Gb 3 can be influenced by the levels of GlcCer.
SLTx Requires ER-DRM Association for Subsequent Intoxication
Because the effect of NB-DGJ is to significantly mitigate toxin potency, we propose that SLTx must require an interaction with DRM in the ER membrane for some crucial step that is obligatory for toxin entry to the cytosol. Because SLTx is thought to co-opt proteins involved in the retro-translocation process associated with ER-associated degradation (ERAD) (Ellgaard and Helenius, 2003; Helenius and Aebi, 2004) , we isolated and analyzed DRM fractions for the presence of these proteins. A proportion of calnexin, ribophorin-1, and Sec61␤ showed coincidence with the DRM fraction in both control ( Figure 7A ) and NB-DGJ-treated HeLa cells ( Figure 7B ), whereas this was not seen for PDI, Derlin-1, or VIMP in either control ( Figure 7C ) or in NB-DGJ-treated cells ( Figure 7D ). The fraction of Sec61␤ in DRM The cells were washed and mechanically lysed with the resulting PNS incubated with 1% Tx-100. DRM were floated in OptiPrep step gradients. The gradients were fractionated, and the presence of bound SLTx was determined by gel electrophoresis and Western blotting and quantified using enhanced chemifluorescence. Gradients were also analyzed by dot-blot for GM 1 (DRM marker) and by gel electrophoresis and blotting for a nonraft marker, the transferrin receptor (TnF-R). Means of three experiments (ϮSEM) are shown. ( Figure 7 ) was similar to that previously visualized after detergent extraction ( Figure 3B ). Recently, a subcompartment of the ER has been identified in which a membranebound ERAD substrate, the precursor of human asialoglycoprotein receptor H2a, accumulated to be observed as punctate structures within the ER upon inhibition of proteasomes in the cytosol (Kamhi-Nesher et al., 2001) . We therefore examined the distribution of Cy2-labeled SLTx internalized for 4 h into HeLa cells after a 5-h inhibition of proteasomes using 10 M MG132 (Figure 8 ). SLTx staining revealed a general reticular pattern consistent with an ER localization in untreated cells (Figure 8 , left), whereas toxin was observed to accumulate in punctate structures, restricted to juxtanuclear and peripheral regions of ER in MG132-treated cells (Figure 8, middle) . This accumulation was consistent with that seen for H2a under identical conditions of proteosomal inhibition (Kamhi-Nesher et al., 2001) . This punctate staining of SLTx was lost after proteasome inhibition and NB-DGJ treatment. Instead, a more general ER reticular staining was revealed (Figure 8, right) . These data suggest that NB-DGJ treatment that reduces the cellular level of GlcCer perturbs the ability of SLTx to localize in areas of the ER that are compatible for subsequent retro-translocation to the cytosol.
DISCUSSION
In this study, we have shown that specific inhibition of ceramide glucosyltransferase with NB-DGJ (Platt et al., 1994) completely protected both HeLa and Vero cells from subsequent intoxication by SLTx. Under the conditions used here, treatment with NB-DGJ altered neither the binding affinity of the toxin to its GSL receptor Gb 3 nor the overall number of receptors. Treatment did lower the recruitment of SLTx into detergent resistant membranes at the cell surface, although presumably, sufficient association remained to permit retrograde transport to the ER (Falguieres et al., 2001; Nichols et al., 2001; Rodighiero et al., 2001; Fujinaga et al., 2003; Hoey et al., 2003; Lencer and Tsai, 2003) . However, NB-DGJ abolished DRM association of SLTx within the ER. Because we interpret DRM to represent lipid microdomains in the original membrane, we propose that the absence of SLTx from such microdomains in the ER membrane is the most likely explanation for the acquired resistance of NB-DGJ-treated cells to this lipid-binding toxin. A number of groups have now provided good evidence for the existence of lipid rafts or microdomains in cell membranes (Friedrichson and Kurzchalia, 1998; Harder et al., 1998; Varma and Mayor, 1998; Pralle et al., 2000; Wilson et al., 2000) . The inclusion or exclusion of certain lipids and proteins and the affinity of a given protein for such rafts can result in a locally different character of the lipid microdomain compared with the surrounding membrane, giving rise to a variety of different cellular functions (London and Figure 6 . The association of SLTx/Gb 3 complexes with DRM is influenced by other GSL. GM95 cells were incubated with 20 M Gb 3 for 48 h in the presence or absence of 20 M GlcSph. The cells were washed, lysed in 0.5% Tx-100 buffer, and DRM were floated on step gradients. The gradients were fractionated, and the levels of Gb 3 and GM3 in both the DRM fraction (A) and the total cellular fraction (B) were quantified. (C) Cyclosporin A-treated (2 h; 10 M) HeLa cells were incubated with 1 M SLTx for 30 min on ice. The cells were washed, mechanically lysed, DRM extracted in 1% Tx-100 buffer, and floated in OptiPrep step gradients. The gradients were fractionated, and the presence of bound SLTx was determined by gel electrophoresis and Western blotting and quantified using enhanced chemifluorescence. Gradients were also analyzed by dotblot for GM 1 (DRM marker) and by gel electrophoresis and blotting for a non-DRM marker, the transferrin receptor (TnF-R). Means of three experiments (ϮSEM) are shown. (D) HeLa cells were pretreated with either media (F) or 10 M cyclosporin A (E) for 2 h before incubation with increasing concentrations of SLTx for 4 h at 37°C. Incorporation of [ 35 S]methionine was used to determine remaining cellular protein synthesis, compared with untreated cells. SEs were Ͻ10%. . Although lipid microdomains on the cell surface tend to be transient (Schutz et al., 2000) , relatively stable microdomains have been visualized in the endocytic pathway (Sharma et al., 2003) where they are proposed to play a role in protein and lipid sorting (Gruenberg, 2001) . Although it is not possible to isolate lipid microdomains or rafts in their native state, the dense packaging of GSL to form liquid ordered (l o ) phases in artificial membranes, and by extension l o domains in cell membranes, gives rise to a characteristic detergent resistance. This in turn allows for a simple biochemical purification of DRM. These are generally interpreted as representing lipid microdomains/rafts and as such they have been used to indicate whether a particular protein associates with lipid rafts in vivo . However, the physical basis for the extraction of lipids with detergents is poorly understood, and care should be taken in experimental interpretation and any extrapolation to their in vivo function. Furthermore, it is unlikely that DRM isolated from cells accurately reflect preexisting structures or organization of the membrane. That said, however, the ability to partition with the DRM fraction could reflect an important membrane-related biochemical property of the specific component in question.
We have shown that recruitment and partitioning of the Gb 3 /SLTx complex to such DRM is influenced by the availability of GlcCer. Whereas the amount of DRM-associated SLTx was reduced upon treatment of cells with either NB-DGJ or cyclosporine A (an inhibitor of the GSL flippase, MDR-1; De Rosa et al., 2004) , it was increased by the addition of exogenous glycosphingosine, a precursor of GlcCer. Indeed, previous transfection of Madin-Darby canine kidney (MDCK) cells with the gene for MDR-1, whose protein product would increase the availability of GlcCer, dramatically increased the sensitivity of these cells to the action of SLTx (Lala et al., 2000) . It has been reported that some types of GSL are capable of modulating the association of specific lipids and proteins within DRM. GlcCer depletion of RAW macrophages increased the detergent resistance of the specific GSL, GD1a (Sillence et al., 2002) . The association of Src proteins with DRM in Lewis lung carcinoma cells was eliminated after depletion of GlcCer, LacCer, and GM3 (Inokuchi et al., 2000) . An in vitro study has also shown that in artificial liposomes containing LacCer, GPI-anchored membrane dipeptidase was sequestered into DRM. However, liposomes alone, or liposomes enriched with different GSL, failed to support DRM association of this protein (Parkin et al., 2001) . This type of modulation may also occur in the opposite direction. For example, addition of GM 1 to MDCK cells rendered a GPI-anchored form of the growth hormone decay accelerating factor protein that was originally detergent resistant, now susceptible to detergent extraction . It has been shown that preferential depletion of GSL in DRM fractions does not affect the levels of sphingomyelin or cholesterol and does not induce signifi- D) were washed, lysed in 1% Tx-100 buffer, and DRM were floated in OptiPrep step gradients. The gradients were fractionated, and the location of the various ER-resident proteins was determined by gel electrophoresis and Western blotting with specific antisera. Gradients were also analyzed by dot-blot for GM 1 (DRM marker) and by gel electrophoresis and blotting for a non-DRM marker, the transferrin receptor (TnF-R). (E) Untreated. cant changes in the distribution of proteins (Shu et al., 2000) . Therefore, the role of GSL in affecting DRM association of other constituents seems to be highly specific. How specific GSL influence whether a particular lipid or protein is found within a lipid microdomain remains unclear. It is interesting to note that an ER monohexosylceramide flippase has been identified (Buton et al., 2002) . This may be effected either directly or indirectly because GlcCer transferase inhibitors can have more than one site of action (Kok et al., 1998) .
Interestingly, the fatty acyl chain length of Gb 3 can affect the intracellular trafficking of STx/SLTx, with binding to the shorter C16 -C18 isoforms promoting transport to the ER and enhancing cytotoxicity (Sandvig et al., 1994; Arab and Lingwood, 1998) . However, tight packing of GSL with long, rather than short, acyl chains is a key feature of lipid microdomain organization . It is therefore reasonable to propose that the presence of GlcCer can increase the affinity of the shorter Gb 3 isoforms that correlate with efficient ER routing and cytotoxicity of SLTx, for DRM association. The data presented here are in agreement with this hypothesis because the effects of inhibiting GSL synthesis with NB-DGJ resulted in a reduction in the amount of Gb 3 -bound SLTx recruited into DRM that correlated with a lower level of GlcCer. It has been demonstrated that association of raft components can be stabilized by cross-linking (Harder et al., 1998) . The receptor-binding SLTx B chains are pentameric, and it is known from the crystal structure that cross-linking of Gb 3 molecules occurs when this toxin binds to the lipid (Ling et al., 1998) . However, our data suggest that Gb 3 cross-linking alone is not sufficient to promote the association of SLTx into tritonextractable DRM, because the binding affinity of the toxin for its receptor was unaltered after NB-DGJ treatment, even though the amount found in DRM was reduced.
NB-DGJ treatment only lowered the DRM association of SLTx at the plasma membrane and had no effect on retrograde transport to the ER. However, NB-DGJ abolished toxin sequestration into DRM at the level of the ER and completely protected cells from SLTx. This suggests that DRM association of SLTx in the ER is an essential requirement for the subsequent intoxication of HeLa cells by SLTx. The gradient in the observed amount of SLTx found with DRM after drug treatment is consistent with the cis-Golgi localization of ceramide glucosyltransferase. After a 2-h inhibition of GlcCer synthesis with NB-DGJ it might be expected that levels of GlcCer in the Golgi and ER be depleted more quickly than at the plasma membrane.
To inactivate ribosomes, the catalytic A1 domain of SLTx must first retrotranslocate across the ER membrane. Little is known about the mechanistic aspects of this process, although certain interactions have been demonstrated for the related toxin CTx and for ricin. Within the ER, the catalytic A-chains of both these toxins are liberated from their respective B-subunits by the action of PDI (Tsai et al., 2001; Spooner et al., 2004) . CTx-A is also unfolded by PDI before its retrotranslocation (Tsai et al., 2001; Tsai and Rapoport, 2002) . The unfolding of other toxins that reach the ER has not been established. However, ricin A chain (RTA) and STx-A have both been shown to interact with negatively charged phospholipid vesicles (Suhan and Hovde, 1998; Day et al., 2002) . Indeed, RTA undergoes significant structural change upon interacting with such lipids , whereas mutations in a proposed membrane-insertion domain of STx-A reduced its interaction with lipids with a concomitant effect on cytotoxicity (Suhan and Hovde, 1998; LaPointe et al., 2005) . Whether these events occur within the ER is unknown, but it remains an appealing possibility that interactions with lipids play an important role in preparing some toxins for the ER membrane translocation step. The negatively charged phospholipid phosphatidylserine (PS) is present within both leaflets of the ER membrane of mammalian cells (Chang et al., 2004) and indeed can be highly enriched within DRM (Pike et al., 2002) . Furthermore, it has been demonstrated that the presence of GlcCer dramatically enhanced the interaction of activated protein C with negatively charged PS vesicles (Yegneswaran et al., 2003) , leading to the hypothesis that microdomains enriched in neutral GSL can promote specific phospholipid-protein interactions. Our data are clearly consistent with this. After NB-DGJ treatment, when the overall level of GlcCer is reduced, SLTx in the ER is absent from isolated DRM. As such, after subunit reduction in the ER lumen, we propose that the SLTx A-chain may not be correctly positioned to interact with negatively charged lipids either because of its nonraft location and/or the absence of GlcCer.
It is widely held that toxin retro-translocation to the cytosol is mediated by the machinery used to discharge newly made but misfolded or orphan proteins to the cytosol for destruction by proteasomes Wesche et al., 1999; Teter et al., 2002 Teter et al., , 2003 , in the process of ERAD. Lipid-induced changes in the secondary and tertiary structure of RTA have been demonstrated previously , leading to the proposition that this might allow interception by ERAD proteins to trigger toxin retro-translocation. A similar situation may apply to SLTx/STx, although this is currently unclear. A novel quality control subcompartment of the ER for membrane-bound ERAD substrates has been identified in mammalian cells (Kamhi-Nesher et al., 2001) . On perturbation of the cytosolic degradation machinery, an H2a ERAD substrate accumulated in cells alongside the ER chaperones calreticulin and calnexin (but not PDI), and was visualized by a punctate juxtanuclear staining of the ER. Pulse-chase analysis and coimmunoprecipition after the synthesis of the mutant H2a revealed an increased interaction between mutant H2a and Sec61-␤, whereas total H2a levels decreased because of proteosomal degradation. It was therefore suggested that interaction with Sec61 could be the rate-limiting step during retro-translocation of ERAD substrates (Kamhi-Nesher et al., 2001) . Our data show that SLTx internalized into HeLa cells gives a similar punctate juxtanuclear ER staining upon inhibition of proteasomes but not when GlcCer is depleted. Furthermore, we found ribophorin, calnexin and Sec61-␤ but not PDI, Derlin-1 or VIMP to be DRM-associated in HeLa cells. Recently, it has been shown that SLTx can interact with a range of ER proteins, including BiP, calnexin, and Sec61, required for transport from the ER lumen to the cytosol (Yu and Haslam, 2005) .
Although detergent extraction has been widely used to postulate in vivo lipid microdomain association, a degree of caution must be taken when relating this to lipid rafts within the ER. However, the use of such methodology to study ER-resident proteins within DRM has been demonstrated previously (Sevlever et al., 1999; Falguieres et al., 2001; Li et al., 2003; Falguieres and Johannes, 2006) . Indeed, it has been proposed that because of the lower content of cholesterol and GSL in the ER membrane, weaker interactions may result between ER-DRM components, such that extraction with 1% Tx-100 may actually result in an underestimation of the association of some ER components with DRM (Sevlever et al., 1999) . We therefore feel that our data showing DRM association of certain ER-resident proteins, with the exclusion of others, is not artificial and could correlate with a proportion of these being partly present within liquid-ordered microdomains in the ER membrane. Indeed, the ER-resident proteins calnexin (Sevlever et al., 1999; Li et al., 2003) and BiP (Falguieres et al., 2001; Falguieres and Johannes, 2006) have previously been isolated in DRM. However, our finding of Sec61-␤ within a DRM fraction contradicts a previous report of a study in yeast, where the homologue Sec61p was soluble in cold Tx-100 (Bagnat et al., 2000) . This might reflect differences between the sterol-mediated ER microdomain organization of yeast and mammalian systems (Arora et al., 2004) and/or their ERAD mechanisms, such as the apparent lack of a calnexin-calreticulin cycle in yeast (Mancini et al., 2003; Helenius and Aebi, 2004) . Other membrane complexes, Derlin-1 and VIMP, have recently been identified as being important for the retro-translocation of major histocompatability complex (MHC) class I molecules mediated by the human cytomegalovirus-encoded glycoprotein US11 (Lilley and Ploegh, 2004; Ye et al., 2004) . Here, we show these proteins cannot be extracted within DRM. As yet, no role for the Derlin-1-containing complex in the dislocation of ER-directed toxins has been established. Furthermore, this complex seems substrate-specific because the dislocation of MHC class I molecules catalyzed by the related human cytomegalovirus-encoded glycoprotein US2 is independent of Derlin-1 (Lilley and Ploegh, 2004) .
In conclusion, our study has revealed the importance of GlcCer levels in determining the fraction of SLTx/Gb 3 complexes found within DRM. This interaction with Gb3 receptors in DRM seems critical not only for transport to the ER but also for a later step at the level of the ER. It is possible that the association with DRM may influence toxin retrotranslocation to the cytosol. Further work is now required to identify the precise molecular composition of ER membrane microdomains and the role(s) these play in facilitating transport of this toxin to the cytosol.
